Anti-CLDN18.2 cell therapy(Integral Molecular)

N/A

Report date: 2024/05/14 17:36:31

Base Information

Drug NameAnti-CLDN18.2 cell therapy(Integral Molecular)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A